Henry I. Miller

Robert Wesson Fellow in Scientific Philosophy and Public Policy

Henry I. Miller, MS, MD, is the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focuses on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

Since coming to the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He is a regulator contributor to Forbes.com and frequently appears on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:



Recent Commentary


Modification Of Embryos Will Someday Treat Hideous Diseases

by Henry I. Millervia National Review
Tuesday, February 2, 2016

On Monday a story in the British newspaper The Independent had this breathless lede: “Scientists in the UK will be allowed to genetically modify human embryos for the first time in history, after they received a licence to go ahead with groundbreaking research into the early stages of human life.” Few in the scientific community would find this earth-shattering.


We Can Beat Zika And Malaria--If The FDA Allows

by John Cohrssen, Henry I. Millervia Forbes
Friday, January 29, 2016

Zika virus infection, the scary new disease for which there is no vaccine or treatment, is “spreading explosively” from Africa and Southeast Asia, according to the head of the World Health Organization.

Joe Biden, Vice-President For Life?

by Henry I. Miller
Wednesday, January 27, 2016

Even with the political silly season offering sideshows like Trump and Sanders, and the cable news networks’ endless parade of bimbo-commentators, NPR has one-upped with them the dumbest interview of all: Florida Atlantic University history professor Ronald Feinman, who is heading a movement to encourage the Democratic nominee for president to pick Joe Biden as his or her running mate.


Instead Of A 'Moonshot,' Cancer Research Needs Reasonable Regulation

by Henry I. Millervia Forbes
Wednesday, January 27, 2016

In the State of the Union speech, the president announced a “moonshot” to cure cancer. It was vintage Obama: high-profile grandstanding accompanied by a profound lack of understanding of how to operate the levers of government to achieve public policy goals.

Blank Section (Placeholder)Analysis and Commentary

When Salmon Tread Water

by Henry I. Millervia Defining Ideas
Wednesday, January 20, 2016

The White House is more interested in political pandering than in science or the law.    

Analysis and Commentary

Bittman Of The 'Times' Finds The Real World Harder Than He Expected

by Julie Kelly, Henry I. Millervia Forbes
Wednesday, January 13, 2016

What happens when a liberal New York Times activist-food columnist decides to start his own business? Grab your organic, non-GMO, gluten-free, locally-sourced, free-trade popcorn, because this will be good.

Analysis and Commentary

S. Philly Grad Led A Good, Patriotic, Productive Life

by Henry I. Millervia Philly.com
Friday, January 8, 2016

As a member of South Philadelphia High School's "Cultural Hall of Fame," I was asked recently to review and rank a new crop of candidates for the honor. 

Analysis and Commentary

Beware Influenza, The Silent Killer

by Henry I. Millervia Forbes
Wednesday, January 6, 2016

It is likely that within the next few weeks, the number of infections with influenza virus will spike in much of the country. Flu cases typically peak in February and can last into May

Analysis and Commentary

Stunted Harvest

by John Cohrssen, Henry I. Millervia Cato Institute
Tuesday, January 5, 2016

Regulatory reform for biotechnology is a tough row to hoe.

Analysis and Commentary

We Have The Scientific Juice To Save Citrus

by Henry I. Millervia Miami Herald
Monday, January 4, 2016

We might be able to avoid the $50 glass of O.J. after all. Farmers in the major U.S. citrus-producing regions — Florida, California, Texas and Arizona, in particular — are facing a plague of epic proportions.